Enhanced Medical Nutrition (EMN) – a food-as-medicine company that commercializes novel and evidence-based medical nutrition products to improve outcomes in surgery – announced a $5 million over-subscribed Series A funding round led by dsm-firmenich Venturing and the Corporate Venture Capital (CVC) arm of Ajinomoto Co., Inc. with participation from PeakBridge, Elder Ventures, angel investors and existing shareholders.
These funds will be allocated to scale the company’s expansion of ENROUTE, which is an innovative nutrition program designed for the dietary management of surgery. By tackling the importance of nutritional requirements for patients undergoing surgical procedures, EMN is dedicated to advance a new standard of care where nutrition technology is leveraged to reduce risk, accelerate recovery, and enhance overall patient outcomes.
KEY QUOTES:
“Nutrition is widely recognized as a critical factor in improving surgical outcomes, yet there remains a significant gap in solutions tailored specifically to patient’s needs. This inflection point is a complete team effort and will enable us to accelerate our mission and vision of supporting surgeons and their care teams and positively influencing patients. We’re thrilled to partner with dsm-firmenich Venturing, the CVC arm of Ajinomoto, PeakBridge, and all our investors as we expand ENROUTE across North America.”
– Eric Zimmerman, Chief Executive Officer and Co-Founder of EMN
“We believe EMN is positioned to significantly impact the standard of care in surgery. The company’s dedication to scientific validation and patient-centric innovation aligns with our vision of leveraging functional ingredients and empowering market-ready solutions that improve human health. This financing marks an exciting step for the company, as they expand their reach and deliver value to a growing market.”
– Arpesh Mehta, Investment Director at dsm-firmenich Venturing
“As an amino acid technology company, Ajinomoto has a strong interest in the impact of nutritional supplementation for surgical patients, from prehabilitation to rehabilitation to healthy aging. This investment in EMN is a starting point of a strategic partnership and a continuation of Ajinomoto’s investment in medical nutrition. We look forward to helping Eric and his team scale their impact as they transform surgical care and improve patient outcomes.”
– Shunji Takehana, Senior Vice President and General Manager of Ajinomoto Innovation Strategy and Corporate Venture Capital
“This investment reflects PeakBridge’s commitment to supporting innovative solutions in the food-as-medicine space. EMN’s approach brings an essential and timely innovation to an underserved market, one that will significantly improve patient outcomes and drive meaningful progress in healthcare nutrition.”
– Gali Artzi, Chief Technology Officer at PeakBridge
